» Articles » PMID: 37088730

Remodeling Collagen Microenvironment in Liver Using a Biomimetic Nano-Regulator for Reversal of Liver Fibrosis

Overview
Journal Adv Sci (Weinh)
Date 2023 Apr 23
PMID 37088730
Authors
Affiliations
Soon will be listed here.
Abstract

Liver fibrosis is a progressive histological manifestation that happens in almost all chronic liver diseases. An unabated liver fibrosis may eventually develop into liver cirrhosis or hepatocellular carcinoma. Yet, the strategy for reversal of liver fibrosis is still limited. Herein, a biomimetic nano-regulator (P-ZIF8-cirDNAzyme) is developed to affect both collagen synthesis and degradation in liver to remodel collagen microenvironment. It is found that Zn (II) interference can efficiently inhibit collagen synthesis in activated hepatic stellate cells (aHSC) by inactivating proline 4 hydroxylase and affecting many fibrosis-related signaling pathways. Meanwhile, Zn (II)-dependent circular DNAzymes (cirDNAzymes) are used to efficiently silence tissue inhibitors of metalloproteinase-1, accelerating the degradation of collagen. They act in concert to recover the balance between collagen deposition and degradation. Additionally, ZIF-8-cirDNAzyme is coated by platelet membrane (PM) for precisely targeting aHSC via PM's inflammatory tropism and CD62p-CD44 interaction. In carbon tetrachloride-induced fibrotic mice, P-ZIF-8-cirDNAzyme shows a potent anti-fibrotic effect, greatly reducing the expression of collagen by 73.12% and restoring liver function nearly to normal. This work proposes a prospective platform enabling ion interference and gene silencing, collectively acting in aHSC for reversal of liver fibrosis.

Citing Articles

Berberine-Loaded PVCL-PVA-PEG Self-Assembled Micelles for the Treatment of Liver Fibrosis.

Zha X, Hao Y, Ke Y, Wang Y, Zhang Y Int J Nanomedicine. 2024; 19:10857-10872.

PMID: 39479175 PMC: 11522012. DOI: 10.2147/IJN.S465214.


Remodeling Collagen Microenvironment in Liver Using a Biomimetic Nano-Regulator for Reversal of Liver Fibrosis.

Liang Y, Wang J, Xu C, Han W, Wu S, Wu Y Adv Sci (Weinh). 2023; 10(18):e2300127.

PMID: 37088730 PMC: 10288244. DOI: 10.1002/advs.202300127.

References
1.
Roehlen N, Crouchet E, Baumert T . Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020; 9(4). PMC: 7226751. DOI: 10.3390/cells9040875. View

2.
Ying M, Zhuang J, Wei X, Zhang X, Zhang Y, Jiang Y . Remote-Loaded Platelet Vesicles for Disease-Targeted Delivery of Therapeutics. Adv Funct Mater. 2018; 28(22). PMC: 6181445. DOI: 10.1002/adfm.201801032. View

3.
Tacke F, Zimmermann H . Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014; 60(5):1090-6. DOI: 10.1016/j.jhep.2013.12.025. View

4.
Adhikari C, Das A, Chakraborty A . Controlled release of a sparingly water-soluble anticancer drug through pH-responsive functionalized gold-nanoparticle-decorated liposomes. Chemphyschem. 2015; 16(4):866-71. DOI: 10.1002/cphc.201402748. View

5.
Bonder C, Clark S, Norman M, Johnson P, Kubes P . Use of CD44 by CD4+ Th1 and Th2 lymphocytes to roll and adhere. Blood. 2006; 107(12):4798-806. DOI: 10.1182/blood-2005-09-3581. View